Advertisement
A vs DHR
Which Stock Would AI Choose? Agilent Technologies (A) vs. Danaher (DHR) Stock Comparison
Key Takeaways
- Agilent Technologies (A) has posted accelerating core revenue growth and margin expansion in recent quarters, while Danaher (DHR) is showing a more gradual, uneven recovery in its core businesses.
- Agilent is a focused life sciences and diagnostics instruments maker, whereas Danaher is a diversified conglomerate spanning biotechnology, life sciences, and diagnostics.
- Danaher carries a significantly larger market capitalization and is pursuing growth through acquisitions, including its recent Masimo purchase, while Agilent is leaning on organic execution through its "Ignite" operating system.
- Both companies are sensitive to biopharma capital spending, China demand, and currency swings, but their near-term growth profiles and valuation multiples differ meaningfully.
- Recent analyst activity has been constructive on both names, though Agilent has shown stronger relative momentum over the past year.
Introduction
Agilent Technologies (A) and Danaher Corporation (DHR) are two of the most widely followed names in the life sciences and diagnostics industry. Although they operate in overlapping end markets, their business structures, growth drivers, and investment profiles differ sharply. Agilent is a focused provider of analytical instruments and laboratory services, while Danaher is a diversified conglomerate that acquires and optimizes businesses across biotechnology, life sciences, and diagnostics. This stock comparison is relevant for investors and traders seeking to understand how these two companies stack up on relative performance, market positioning, and momentum in the current environment.
A Overview and Recent Performance
Agilent Technologies provides application-focused solutions across life sciences, diagnostics, and applied chemical markets, organized into three reporting segments: Life Sciences and Diagnostics, Agilent CrossLab (services and consumables), and Applied Markets. In recent quarters, the company has benefited from a strengthening instrument-replacement cycle, robust biopharma demand, and improving conditions in China.
Recent market activity reflects a notable acceleration in Agilent's fundamentals. In its most recently reported quarter, revenue reached approximately $1.88 billion with core growth of roughly 7.3%, exceeding guidance, while operating margin expanded sharply on a year-over-year basis. Management cited double-digit pharmaceutical growth, strong momentum in GLP-1 (a class of diabetes and obesity drugs) related revenue, and improving advanced-materials demand tied to semiconductors. The company's "Ignite" operating system has supported margin expansion and pricing gains, and its book-to-bill ratio has remained above 1.0 for ten consecutive quarters, indicating sustained order momentum.
DHR Overview and Recent Performance
Danaher Corporation is a diversified global science and technology company operating through three segments: Biotechnology, Life Sciences, and Diagnostics. Its operating model, the Danaher Business System (DBS), is a framework for continuous improvement applied across its portfolio. Danaher's growth strategy is heavily acquisition-driven, and it recently completed the purchase of Masimo, a patient-monitoring and pulse oximetry company, for approximately $9.8 billion.
Danaher's recent performance reflects a gradual, uneven recovery. In recent quarters, the company's Biotechnology segment has been the standout, with double-digit growth driven by strengthening bioprocessing demand, while Diagnostics has lagged. Core revenue growth has remained in the low-to-mid single digits, and management has guided to a modest full-year core growth range while raising its earnings outlook. The company has also announced an artificial intelligence collaboration focused on autonomous science, signaling investment in next-generation laboratory automation.
Trending AI Robots
For traders looking to apply a systematic, data-driven approach to names like A and DHR, Tickeron's Trending AI Robots page offers a curated view of the platform's artificial intelligence trading bots. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, but only the strongest performers best suited to prevailing market conditions earn a place in the Trending AI Robots section. These bots vary widely in trading style, strategy, timeframe, performance statistics, and the tickers they cover, allowing users to explore approaches ranging from short-term momentum to longer-horizon trend following. Reviewing this section can help you identify automated strategies currently aligned with the market environment.
Head-to-Head Comparison
The most important contrast between these two companies is structure and focus. Agilent operates as a more concentrated, instruments-and-services business, which can translate into faster margin expansion when its end markets recover. Danaher, by contrast, is a much larger, diversified conglomerate whose acquisition-driven model spreads risk across multiple segments but can also dilute near-term growth when parts of the portfolio lag.
On momentum, Agilent has recently shown a stronger growth trajectory, with high-single-digit core growth and expanding margins, while Danaher's core growth has been more modest and uneven, with strength concentrated in bioprocessing. On valuation and scale, Danaher is the larger company by market capitalization and trades at a higher price-to-earnings (P/E) multiple relative to near-term earnings, reflecting investor expectations for a broader recovery. Agilent carries a lower forward multiple but has demonstrated more consistent recent execution.
Risk profiles also differ. Both companies are exposed to biopharma funding cycles, China demand, and foreign-exchange (FX) swings. Agilent's smaller scale makes it more sensitive to academic and government spending, which has been soft. Danaher's diversification provides stability but adds integration risk from recent acquisitions such as Masimo.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would currently lean toward Agilent Technologies (A) on a relative momentum and trend-consistency basis. Agilent's accelerating core growth, expanding margins, and sustained book-to-bill strength suggest a more clearly defined near-term trend than Danaher's gradual and uneven recovery. That said, Danaher's diversification, scale, and cash generation make it a more stable long-term compounder, and its forward valuation reflects expectations of a broader turnaround. The AI-driven assessment would likely favor Agilent for trend and catalyst positioning in the current environment, while recognizing Danaher's advantages in stability and diversification. This reflects a probabilistic view of current conditions rather than a definitive prediction.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a Hold and DHR is a StrongBuy.
Aroon Indicator for A shows an upward move is likely
A's Aroon Indicator triggered a bullish signal on October 28, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 209 similar instances where the Aroon Indicator showed a similar pattern. In 137 of the 209 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 66%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +3.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where A advanced for three days, in 187 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
Bearish Trend Analysis
The 10-day RSI Indicator for A moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 20 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 69 cases where A's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 64%.
The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on A as a result. In 57 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 66%.
The Moving Average Convergence Divergence Histogram (MACD) for A turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 26 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 59%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where A declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
A broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 10 (best 1 - 100 worst), indicating outstanding price growth. A’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.784) is normal, around the industry mean (66.911). P/E Ratio (34.807) is within average values for comparable stocks, (2.514). Projected Growth (PEG Ratio) (1.447) is also within normal values, averaging (3.473). Dividend Yield (0.006) settles around the average of (0.002) among similar stocks. P/S Ratio (5.910) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 45 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 46 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 70 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. A’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock better than average.
DHR in +3.05% Uptrend, advancing for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where DHR advanced for three days, in 180 of 323 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on DHR as a result. In 47 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 53%.
The Aroon Indicator entered an Uptrend today. In 108 of 195 cases where DHR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 55%.
Bearish Trend Analysis
The 10-day RSI Indicator for DHR moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 13 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 46%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 65 cases where DHR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 58%.
The Moving Average Convergence Divergence Histogram (MACD) for DHR turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 32 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 68%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DHR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.
DHR broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.141) is normal, around the industry mean (66.911). P/E Ratio (41.654) is within average values for comparable stocks, (2.514). Projected Growth (PEG Ratio) (1.361) is also within normal values, averaging (3.473). Dividend Yield (0.007) settles around the average of (0.002) among similar stocks. P/S Ratio (5.900) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 19 (best 1 - 100 worst), indicating outstanding price growth. DHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 77 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DHR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
A | DHR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 78 | 28 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 70 | 100 | |
SMR RATING 1..100 | 45 | 77 | |
PRICE GROWTH RATING 1..100 | 10 | 19 | |
P/E GROWTH RATING 1..100 | 46 | 56 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (15) in the Medical Specialties industry is in the same range as A (24) in the Biotechnology industry. This means that DHR’s stock grew similarly to A’s over the last 12 months.
A's Profit vs Risk Rating (70) in the Biotechnology industry is in the same range as DHR (100) in the Medical Specialties industry. This means that A’s stock grew similarly to DHR’s over the last 12 months.
A's SMR Rating (45) in the Biotechnology industry is in the same range as DHR (77) in the Medical Specialties industry. This means that A’s stock grew similarly to DHR’s over the last 12 months.
A's Price Growth Rating (10) in the Biotechnology industry is in the same range as DHR (19) in the Medical Specialties industry. This means that A’s stock grew similarly to DHR’s over the last 12 months.
A's P/E Growth Rating (46) in the Biotechnology industry is in the same range as DHR (56) in the Medical Specialties industry. This means that A’s stock grew similarly to DHR’s over the last 12 months.
| A | DHR | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 71% | 7 days ago 46% |
| Stochastic ODDS (%) | 1 day ago 64% | 1 day ago 58% |
| Momentum ODDS (%) | 1 day ago 66% | 1 day ago 53% |
| MACD ODDS (%) | 1 day ago 59% | 1 day ago 68% |
| TrendWeek ODDS (%) | 1 day ago 62% | 1 day ago 57% |
| TrendMonth ODDS (%) | 1 day ago 63% | 1 day ago 58% |
| Advances ODDS (%) | 1 day ago 62% | 1 day ago 56% |
| Declines ODDS (%) | 4 days ago 63% | 4 days ago 59% |
| BollingerBands ODDS (%) | 1 day ago 71% | 1 day ago 67% |
| Aroon ODDS (%) | 1 day ago 66% | 1 day ago 55% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 2 FA rating(s) are green while DHR’s FA Score has 2 green FA rating(s).
- A’s FA Score: 2 green, 3 red.
- DHR’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 2 TA indicator(s) are bullish while DHR’s TA Score has 3 bullish TA indicator(s).
- A’s TA Score: 2 bullish, 6 bearish.
- DHR’s TA Score: 3 bullish, 5 bearish.
Price Growth
A (@Medical Specialties) experienced а -2.37% price change this week, while DHR (@Medical Specialties) price change was +0.37% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.74%. For the same industry, the average monthly price growth was -6.91%, and the average quarterly price growth was +44.46%.
Reported Earning Dates
A is expected to report earnings on Nov 23, 2026.
DHR is expected to report earnings on Feb 03, 2027.
Industries' Descriptions
@Medical Specialties (-3.74% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To DHR | 1D Price Change % | ||
|---|---|---|---|---|
| DHR | 100% | +2.09% | ||
| TMO - DHR | 73% Closely correlated | +1.12% | ||
| RGEN - DHR | 68% Closely correlated | -0.04% | ||
| BIO - DHR | 64% Loosely correlated | +1.35% | ||
| A - DHR | 60% Loosely correlated | +0.97% | ||
| BRKR - DHR | 58% Loosely correlated | +12.90% | ||
More | ||||